Solventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow SOLV
Solventum Corporation (SOLV) Revenue growth
Solventum Corporation's revenue growth over the twelve months to 30 June 2026 was −0.93%, down 1.8 percentage points from fiscal 2025 (0.86%). That is below the Medical Instruments & Supplies industry median of 8.85% and below the Healthcare sector median of 8.27%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 0.86% | 0.16 |
| FY2024 | 0.70% | (0.12) |
| FY2023 | 0.82% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 2.22% | 5.26 |
| Mar 2026 | −3.04% | 0.67 |
| Dec 2025 | −3.71% | (4.38) |
| Sep 2025 | 0.67% | (3.17) |
| 6 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| RGEN Repligen Corporation compare | 16.5% |
| WST West Pharmaceutical Services, Inc. compare | 12.4% |
| ATR AptarGroup, Inc. compare | 8.93% |
| ALC Alcon compare | 8.34% |
| BAX Baxter International Inc. compare | 5.36% |
| COO The Cooper Companies, Inc. compare | 4.73% |
| ALGN Align Technology, Inc. compare | 4.41% |
| SOLV Solventum Corporation | −0.93% |
| AVTR Avantor, Inc. compare | −1.57% |
| Medical Instruments & Supplies industry median | 8.85% |
| Healthcare sector median | 8.27% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on SOLV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- The full statement